ENDOSCOPIC AND HISTOLOGIC REMISSION AFTER 2 YEARS TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS

Fernando Magro  ¹     Laurent Peyrin-Biroulet  ²     Taku Kobayashi  ³     Vipul Jairath  ⁴     Alissa Walsh  ⁵     Britt Christensen  ⁶     Jianmin Wu  ⁷     Brad Dain  ⁸     Isabel Redondo  ⁸     Bruce E. Sands  ^9    
1 Centro Hospitalar São João, Porto, Portugal
² Nancy University Hospital, Vandoeuvre-les-Nancy, France
³ Kitasato University Kitasato Institute Hospital, Minato-ku, Japan
⁴ Western University, London, Canada
⁵ NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom
⁶ University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia
⁷ Eli Lilly and Company, Indianapolis, United States
⁸ TechData Service, King of Prussia, United States
⁹ Icahn School of Medicine at Mount Sinai, New York, United States

Topic
Endoscopy, Histopathology, IBD

Session
The new kids on the block for IBD: Part 1

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)